The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Some big deals in the second quarter have raised hopes that takeouts are back.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.